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Abstract
Background: There is emerging evidence regarding the efficacy of exercise training to improve exercise capacity
for individuals with non-small cell lung cancer (NSCLC). Cardiopulmonary exercise testing (CPET) is the gold
standard measure of exercise capacity; however this laboratory test has limitations for use in research and clinical
practice. Alternative field walking tests are the six-minute walk test (6MWT), incremental-shuttle walk test (ISWT) and
endurance-shuttle walk test (ESWT); however there is limited information about their clinimetric properties in
NSCLC. Aims: In NSCLC to determine the 1) criterion validity of the 6MWT, ISWT and ESWT against CPET; 2)
construct validity of the 6MWT, ISWT and ESWT against measures of function, strength, respiratory function and
health-related quality of life (HRQoL); and 3) clinical applicability of the tests.
Methods: Twenty participants (40 % male, mean ± SD age 66.1 ± 6.5 years) with stage I-IIIb NSCLC completed the
6MWT, ISWT, ESWT and CPET within six months of treatment. Testing order was randomised. Additional measures
included Eastern Cooperative Oncology Group Performance-Status (ECOG-PS, function), respiratory function, hand-
grip dynamometry and HRQoL. Correlations and regression analyses were used to assess relationships.
Results: The ISWT demonstrated criterion validity with a moderate relationship between ISWT distance and CPET peak
oxygen consumption (r = 0.61, p = 0.007). Relationships between CPET and six minute walk distance (6MWD)
(r = 0.24, p = 0.329) or ESWT time (r = 0.02, p = 0.942) were poor. Moderate construct validity existed for the 6MWD and
respiratory function (forced vital capacity % predicted r = 0.53, p = 0.019; forced expiratory volume in the first second %
predicted r = 0.55, p = 0.015). There were no relationships between the walking tests and measures of function,
strength or HRQoL. The ESWT had a ceiling effect with 18 % reaching maximum time. No floor effects were seen in the
tests. The mean ± SD time required to perform the individual 6MWT, ISWT and ESWT was 12.8 ± 2.5, 14.7 ± 3.7 and
16.3 ± 5.0 min respectively; in comparison to CPET which was 51.2 ± 12.7 min. Only one assessor was required to
perform all field walking tests and no adverse events occurred.
Conclusions: The ISWT is a promising measure of functional exercise capacity in lung cancer. Findings need to be
confirmed in a larger sample prior to translation into practice.
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Background
Non-small cell lung cancer (NSCLC) is associated with
high disease burden, physical hardship and significant
morbidity [1–3]. Functional decline is rapid after diagno-
sis [4, 5] and impairment in exercise capacity, physical
function and health-related quality of life (HRQoL) can
ensue [6, 7]. Exercise is a non-pharmacological interven-
tion with great potential benefit for people with NSCLC.
Studies to date show that exercise interventions are as-
sociated with improvements in exercise capacity for pa-
tients with NSCLC [8–10]; however important questions
remain as to the most suitable test to assess exercise
capacity in both research and clinical settings.
Exercise capacity is “the maximal capacity of an indi-
vidual to perform aerobic work or maximal oxygen con-
sumption” [11]. The gold standard measure of exercise
capacity is cardiopulmonary exercise testing (CPET)
used to determine peak oxygen consumption (VO2peak)
[12]. Symptom-limited CPET is safe in patients with
NSCLC [12, 13] and pre-operative VO2peak, measured
by CPET, is a strong and independent predictor of sur-
vival [14]. However CPET has limitations for use in clin-
ical practice and research studies: this laboratory test is
expensive, time consuming and requires experienced
technicians. In the NSCLC exercise studies published to
date, CPET has been used less frequently than alterna-
tive field walking tests [8–10].
The six-minute walk test (6MWT), incremental-shuttle
walk test (ISWT) and endurance-shuttle walk test (ESWT)
are commonly used field walking tests which measure
functional exercise capacity [15]. These field walking tests
are alternatives to laboratory-based CPET, however they
are often criticised and considered not valid or sensitive
enough to detect changes in exercise capacity because
they may not sufficiently stress the cardiovascular system
in individuals without concomitant comorbid disease [16].
Therefore understanding the validity of these tests in
NSCLC is vital. Whilst a test may have excellent validity
as a measurement tool in one patient group, these findings
cannot always be extrapolated to other patient groups
[17]. In NSCLC specific features including fatigue, cancer
cachexia and loss of peripheral muscle strength can
uniquely influence performance [7, 18]. Therefore consid-
eration of the ability of the test to measure what it is
intended to measure, that is, how well the data relate to
data obtained from the gold standard test (CPET) (criter-
ion validity); and how well the test obtains data, as
hypothesised, when compared to a test measuring a simi-
lar construct (construct validity) is important [17, 19]. The
6MWT is the most commonly used field walking test in
NSCLC [20] however there is a lack of evidence of its cri-
terion validity in NSCLC [20]. In chronic obstructive pul-
monary disease (COPD) there is a moderate relationship
between 6MWT and CPET (r = 0.59–0.93) [21, 22]. The
ISWT and ESWT are less commonly used in NSCLC but
have emerged over the last decade as robust measures of
exercise capacity in COPD [15, 23, 24]. These tests have
the advantage over the 6MWT in that they are externally
paced potentially achieving more valid results.
The primary aims of this study were, therefore: 1) to de-
termine the criterion validity of the 6MWT, ISWT and
ESWT against CPET in lung cancer. The primary hypoth-
esis was that the 6MWT, ISWT and ESWT would be
moderately to strongly correlated (r > 0.5) with VO2peak
measured by CPET. Secondary aims were to: 2) determine
the construct validity of the 6MWT, ISWT and ESWT
against measures of physical function, muscle strength,
respiratory function and HRQoL; and 3) determine the
clinical applicability of the tests. The Strengthening the
Reporting of Observational Studies in Epidemiology
(STROBE) guidelines [25] and the COnsensus-based
Standards for the selection of health status Measure-
ment INstruments (COSMIN) guidelines [19, 26–28]
were followed to report this study.
Methods
Study design, setting and participants
This was a single centre prospective observational co-
hort study conducted at a tertiary metropolitan hospital
in Melbourne, Australia from July 2013 to December
2014. The study had ethical approval from Melbourne
Health Human Research Ethics Committee and written
consent was obtained from participants. Participants had
histologically confirmed NSCLC; were scheduled to re-
ceive or had received treatment within the past six
months; and an Eastern Cooperate Oncology Group Per-
formance Status (ECOG-PS) of 0–2. Exclusion criteria
included inability to provide consent; cognitive disorder;
extensive skeletal or visceral metastases; stage IV disease
post-treatment; co-morbidity preventing exercise testing
(for example stroke or amputation); insufficient English
language skills to complete a questionnaire; or a contra-
indication to CPET as recommended by the American
Thoracic Society (ATS) [29].
Procedure
Consecutive patients admitted through the thoracic sur-
gery unit between July 2013 and September 2014 were
screened for eligibility. In addition a convenience sample
of new patients admitted through the lung oncology out-
patient clinics were screened. All patients meeting eligi-
bility criteria were approached.
Assessments were performed at one time-point within
two to six months of the participant receiving their last
treatment (surgery or chemotherapy) or pre-treatment
(if the patient was pre-operative). Each participant com-
pleted the 6MWT, ISWT, ESWT and CPET, along with a
range of additional tests. Participants completed these
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assessments over two testing sessions which were no
longer than seven days apart. Participants were stable
and unchanged in the time between completing the tests
and did not receive medical or exercise intervention be-
tween testing sessions (participants were specifically
asked this between testing sessions). In between tests
participants were given a rest to ensure they had recov-
ered (assessed by return to resting heart rate) prior to
completing the next test. The rest was a minimum of
15 min.
The order of testing was randomised to account for
any order effect. Due to the fact that the ESWT can-
not be completed without a prior ISWT (as the
ESWT speed is set by the results of the ISWT), the
ISWT and ESWT were considered as a block for ran-
domisation. Simple randomisation was undertaken
using an off-site computer generated random number
table and sequentially numbered sealed opaque enve-
lopes prepared by personnel not involved in the
study. For each consented participant the next con-
secutive assignment envelope was opened and the
study coordinator was notified of the allocation of
testing order. Assessors were not blinded to order al-
location, but participants were not made aware of the
testing order prior to completing tests.
Field walking tests
Six minute walk test
The 6MWT is a self-paced field walking test which mea-
sures the distance in meters (m) an individual can walk
along a flat straight corridor 30 m long in six minutes
[15]. The 6MWT was conducted according to published
ATS and European Respiratory Society (ERS) recom-
mendations [15, 30]. Duplicate tests were completed to
account for the learning effect and the best test result
was used in analyses [15]. In patients with COPD the
6WMT is reliable (intra-class correlation coefficients
[ICCs] = 0.82-0.99), valid (CPET VO2peak r = 0.4-0.6)
and sensitive to change [15, 31].
Incremental shuttle walk test (Department of Respiratory
Medicine, Glenfield Hospital, Leicester, UK)
The ISWT is an externally-paced incremental field walk-
ing test [15, 23]. The test measures the distance in m an
individual can walk around a 10 m shuttle course paced
according to an incremental speed dictated by an audio
recording [23]. The test speed increases every minute
and the test finishes when the participant can no longer
maintain the desired speed. The starting (lowest) speed
is 0.50 m/s and final (highest) speed is 2.37 m/s; with a
maximum possible distance achieved of 1020 m. Dupli-
cate tests were completed to account for the learning ef-
fect and the best test result was used in analyses [15].
The test result was also used to predict VO2peak using
published equations [23, 24]. In COPD the ISWT is reli-
able (ICC = 0.88), valid (CPET VO2peak r = 0.75-0.88)
and sensitive to change [15, 31].
Endurance Shuttle Walk Test (Department of Respiratory
Medicine, Glenfield Hospital, Leicester, UK)
The ESWT is an externally-paced field walking test
which measures the time in seconds an individual can
walk at a pre-set speed [23]. The ESWT is similar to the
ISWT however the walking speed remains constant
throughout the test (set at 85 % of maximum walking
performance from the ISWT) [23]. The participant walks
for as long as possible up to a maximum of 20 min
(patients are not made aware of the time limit). A single
ESWT was performed as duplicate tests do not appear
necessary to account for any learning effect [15, 31].
Throughout the tests oxygen saturation and heart rate
were monitored using a portable pulse oximeter. Dyspnoea
and leg fatigue were measured pre and post-test on the
0–10 modified BORG scale [32]. The differences between
pre-test BORG scores (including duplicate 6MWT/ISWT)
were assessed to determine participant stability between
testing. The minimal important difference in BORG dys-
pnoea for patients with COPD is 1 point out of 10 [33].
The time and number of staff required to conduct each
test was recorded as well as any adverse events.
Additional measures
Cardiopulmonary Exercise Testing was performed to de-
termine VO2peak. Prior to conducting CPET, respiratory
function tests (spirometry) were performed as recom-
mended and these were conducted according to the ATS
and ERS guidelines [34, 35]. Measurements were made
using Sensormedics Vmax Encore, 22D (Sensormedics,
Yorba Linda, Ca, USA). Cardiopulmonary exercise test-
ing was performed using a Sensormedics Vmax Encore,
229D (Sensormedics, Yorba Linda, Ca, USA) exercise
system and a Ergoline Via Sprint 150P cycle ergometer
(Lindenstrabe 5, 72475 Bitz, Germany). A 12-lead elec-
trocardiography was monitored using a GE Cardiosoft
Version 6.51 electrocardiography system (GE Healthcare,
GE Marquette Medical Systems, 8200 West Tower Ave,
Milwaukee, WI 53223. USA). Two minutes of rest data
were collected prior to an incremental test with the
workload increasing every minute. The workload incre-
ments were selected using the equations from Jones [36]
and the test continued until symptomatic limitation. The
cycle exercise test data were calculated using 30-s aver-
ages. Symptomatic levels of breathlessness in combin-
ation with participant data (heart rate) were used to
establish if the test was maximal. Percentage of predicted
VO2peak was calculated according to normative equa-
tions by Jones [36]. The time required to conduct the
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test (including initial spirometry tests, CPET set-up and
CPET instructions) was recorded.
Physical function was measured using the ECOG-PS
rated by the participant [37]. Participants were also
asked if they had any limitations to walking as far as they
needed to. Hand-grip strength was measured using a
Jamar hydraulic hand-grip dynamometer, and was taken
as the best of three measures [38]. Health-related quality
of life was measured using the European Organization
for the Research and Treatment of Cancer questionnaire
and lung cancer module (EORTC QLQ-C30-LC13) [8,
39]. Medical and social demographics were obtained in-
cluding age, sex, body mass index, cancer stage, histo-
logical type, treatment type/status and smoking history.
Comorbidities were scored using the simplified Colinet
comorbidity score [40].
Sample size
For 80 % power and a significant difference (alpha
two tailed 0.05) between the correlation coefficients
of the null hypothesis (rho0 = 0.50) and alternative hy-
pothesis (rho1 = 0.80) (95 % CI = 0.50-0.93) 16 partici-
pants were required. To account for an estimated
25 % drop out rate and missing data the sample size
was increased to 20.
Statistical analyses
Data were analysed through SPSS Windows Version 22.0
(SPSS, Chicago, IL, USA). Data were assessed for nor-
mality using the Kolmogorov-Smirnov statistic. Paramet-
ric data are presented as mean and standard deviation
(SD), and non-parametric data are presented as median
and inter-quartile range (IQR). Participant stability be-
tween testing was assessed using paired t-tests to exam-
ine differences in baseline (pre-test) dyspnoea and leg
fatigue before each test (6MWTx2, ISWTx2, ESWT and
CPET).
Pearson’s correlation coefficient was used to assess the
bivariate relationships between test scores (6MWT-m,
ISWT distance-m, ESWT time-seconds and CPET
VO2peak-ml/kg/min) [41]. Coefficients were interpreted
as: little (0.00–0.25), fair (0.25–0.50), moderate (0.50–0.75)
and strong association (0.75–1.0) [17]. Simple linear re-
gression was used to further explore relationships between
the field tests and CPET VO2peak. The CPET VO2peak
was the dependent variable and 6MWT, ISWT distance or
ESWT time were the independent variables. Potential co-
variates were medical and social demographics (listed in
Table 1), physical function, hand-grip strength, respiratory
function and HRQoL. Potential covariates with significant
univariate correlation with the outcome of interest (CPET
VO2peak) were included in the model if collinearity was
not identified. Alpha was set at 0.05 for all analyses.
Floor and ceiling effects of the tests were determined
using the percentage of occasions when participants scored
the lowest (6MWT= 0 m, ISWT= 0 m, ESWT= 0 s) or
highest result (ISWT= 1020 m, ESWT= 1200 s) possible
for the tests respectively.
Results
Between August 2013 and December 2014, 158 patients
were screened, of whom 38 % (n = 60/158) were eligible
and approached (Fig. 1). The consent rate was 33 % (n =
20/60). The main reasons for decline were “too far to
travel to the hospital for testing” 37 % (n = 15/40) or
“not interested” 27 % (n = 11/40). Twenty patients with
lung cancer were studied (Fig. 1).
The characteristics of the cohort studied are reported
in Table 1. For the 6MWT, ISWT and CPET data were
available for 95 % (n = 19) of the cohort and for the
ESWT data were available for 85 % (n = 17). Data were
not missing from the same 19 individuals for the
6MWT, ISWT and CPET. A technical failure of equip-
ment during one CPET resulted in missing data from
one of the 20 participants, although all 20 participants
undertook CPET testing. The median [IQR] time be-
tween the testing sessions was 2.5 [0–5.7] days. In this
time participants were stable and unchanged: there was
no statistically significant difference in baseline (pre-test)
dyspnoea between each test (p > 0.05). There was a small
statistically significant difference between baseline leg fa-
tigue for the first and second 6MWT (mean difference
[95 % CI] = 0.5 [0.1-1.0]points, p = 0.019) although this
difference is not likely to be clinically significant [33];
and between the first 6MWT and the ESWT (mean dif-
ference [95 % CI] =1.7 [0.4-3.0]points, p = 0.015). There
were no other differences in baseline leg fatigue between
tests (p > 0.05).
Criterion validity
The ISWT exhibited moderated criterion validity with
CPET VO2peak (r = 0.61 [95 % CI = 0.20-0.88] p = 0.007)
(Fig. 2). There was a moderate relationship between ISWT
predicted VO2peak and CPET VO2peak (ml/kg/min) (r =
0.61 [95 % CI = 0.16-0.88] p = 0.008); however the ISWT
tended to under-predict VO2peak in comparison to
VO2peak measured using CPET (Table 2). Simple linear
regression demonstrated the ISWT and forced expiratory
volume in the first second (FEV1) to be significant deter-
minants of CPET VO2peak together explaining 59 % of
the variance (ISWT B coeff = 0.55, FEV1 B coeff = 0.47,
p = 0.001). The 6MWT and ESWT exhibited a poor rela-
tionship with CPET VO2peak: 6MWD (r = 0.24 [95 %
CI = −0.12-0.69] p = 0.329) and ESWT (r = 0.02 [95 %
CI = −0.43-0.53] p = 0.942) (Fig. 2).
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Construct validity
There was a strong relationship between the 6MWT and
ISWT (r = 0.80 [95 % CI = 0.64-0.93] p < 0.005). Weaker
relationships existed between the ESWT and the 6MWT
(r= 0.42 [95 % CI = −0.11-0.73] p = 0.101) or ISWT (r =
0.31 [95 % CI = −0.22-0.65] p = 0.224).
The 6MWT exhibited moderate construct validity with
respiratory function (forced vital capacity % predicted r =
0.53 [95 % CI = 0.24-0.86] p = 0.019; FEV1 % predicted r =
0.55 [95 % CI = 0.30-0.76] p = 0.015). Small non-
significant relationships were seen between FEV1 % pre-
dicted and both the ISWT (r = 0.43 [95 % CI = 0.26-0.68]
p = 0.065) and ESWT (r = 0.45 [95 % CI = −0.11-0.80] p =
0.067).
Lower pain levels were associated with better perform-
ance in the ESWT (r = 0.72 [95 % CI = 0.37-0.96]
p = 0.002). There were no relationships between ECOG-PS
or the EORTC-QLQ-C30 physical function domain score
and performance in the field walking tests or CPET. There
were no relationships between hand-grip strength or
HRQoL and the field walking tests.
Table 1 Medical and social demographics (n = 20)
Variable Mean ± SD or
n (%)
Age, years 66.1 ± 6.5
Gender, male 8 (40.0 %)
Body mass index, kg/m2 28.5 ± 4.0
Colinet comorbidity score, median [IQR] 9.0 [8.0 – 10.0]
COPD diagnosis 7 (35.0 %)
Smoking status
Never smoker 2 (10.5 %)
Current smoker 2 (10.5 %)
Ex-smoker 15 (78.9 %)
Unknown [1]
Smoking pack year history 38.4 ± 19.6
Lung cancer stage
Stage I 12 (60.0 %)
Stage II 5 (25.0 %)
Stage III 3 (15.0 %)
Lung cancer histological type
Adenocarcinoma 15 (75.0 %)
Squamous cell carcinoma 2 (10.0 %)
Other 3 (15.0 %)
Treatment status at time of testing
Pre-treatment 3 (15.0 %)
Post-surgery only 12 (60.0 %)
Post-surgery and chemotherapy 5 (25.0 %)
Type of thoracic surgery
Lobectomy 14 (70.0 %)
Pneumonectomy 3 (15.0 %)
N/A (pre-operative) 3 (15.0 %)
Time since last treatment
(surgery or chemotherapy), daysa
134.9 ± 43.9
Use of a gait aid
No 20 (100 %)
Self-reported limitation to walking 4 (20 %)
ECOG-PS, patient rated
0, fully active 11 (57.9 %)
1, walking but only light work 8 (42.1 %)
Unknown [1]
Hand-grip strength, kilograms 14.8 ± 7.4
Respiratory function
FEV1, litres 1.9 ± 0.4
FEV1 % predicted 80.6 ± 16.0
FVC, litres 3.0 ± 0.8
FVC, % predicted 101.8 ± 22.7
Physical activity levels
Sedentary (0 min/week) 8 (40.0 %)
Table 1 Medical and social demographics (n = 20) (Continued)
Insufficient (1–149 min/week) 7 (35.0 %)
Sufficient (150+ minutes/week) 5 (25.0 %)
Time spent watching television,
hours/day, median [IQR]
3.0 [2.2 – 5.4]
HRQoL
Global quality of life domain 76.7 ± 17.9
Physical function domain 77.5 ± 14.5
Social situation
Home with family 10 (50.0 %)
Home alone, independent 8 (40.0 %)
Retirement village 2 (10.0 %)
Employment status
Working full time 1 (5.0 %)
Working part time 1 (5.0 %)
Temporary or sick leave 1 (5.0 %)
Not employed 3 (15.0 %)
Retired 14 (70.0 %)
Highest level of education obtained
PhD or Master’s degree 1 (5.0 %)
Bachelor’s degree 2 (10.0 %)
Trade or community certificate 2 (10.0 %)
Completed secondary school 4 (20.0 %)
Some secondary school 11 (55.0 %)
Abbreviations: % percent; COPD Chronic Obstructive Pulmonary Disease; ECOG-PS
Eastern Cooperate Oncology Group- Performance status; IQR inter-quartile range;
kg kilograms; m meters; n number; PhD Doctor of Philosophy; SD
standard deviation
aonly participants who were post-treatment included
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All three field walking tests could discriminate be-
tween people who reported having walking limitations
(p < 0.05), which was not the case for CPET. The mean
difference [95 % CI] between people with self-rated
walking limitations on the 6MWT, ISWT and ESWT
were 163.5 [97.9-229.2]m, 171.0 [46.0-296.0]m and 531.1
[80.6-981.7]seconds respectively.
Clinical applicability
Tests results are provided in Table 2. The six minute walk
distance (6MWD) ranged from 286-590 m. No floor or
ceiling effect was observed. From pre to post-test there
were statistically significant increases in dyspnoea (mean
difference [95 % CI] = 2.5 [1.9-3.2] points, p < 0.0005) and
leg fatigue (mean difference [95 % CI] = 1.7 [0.6-2.7]points,
p = 0.003) (Table 3). In comparison the increase in dys-
pnoea and leg fatigue from pre to post CPET were mean
difference [95 % CI] 4.2 [3.0-5.3]points (p < 0.005) and 4.9
[3.6-6.3]points (p < 0.005) respectively (Table 3).
The ISWT distance ranged from 170-710 m, and the pre-
dicted VO2peak from this test ranged from 8.4-21.9 ml/kg/
min. No floor or ceiling effects were observed. From pre to
post-test there were statistically significant increases in
dyspnoea (mean difference [95 % CI] = 3.7 [2.7-4.6]points,
p < 0.0005) and leg fatigue (mean difference [95 % CI] = 2.6
[1.5-3.6]points, p < 0.0005) (Table 3).
The ESWT time ranged from 114-1200s. The ESWT
was performed on levels ranging from 6–16. A ceiling ef-
fect was seen with 17.6 % (n = 3/17) of participants reach-
ing the end of the test (1200 s). No floor effect was seen.
From pre to post-test there were statistically significant
increases in dyspnoea (mean difference [95 % CI] = 3.8
[2.5-5.2]points, p < 0.0005) and leg fatigue (mean difference
[95 % CI] = 2.8 [1.5-4.1] p < 0.0005 (Table 3).
The mean ± SD time required to perform the individ-
ual 6MWT, ISWT and ESWT were 12.8 ± 2.5 min,
14.7 ± 3.7 min and 16.3 ± 5.0 min respectively. In com-
parison the time required to perform the CPET was
Fig. 1 Consort diagram. Abbreviations: 6MWD six minute walk distance; CPET cardio-pulmonary exercise test; ESWT endurance shuttle walk test;
ISWT incremental shuttle walk test; NSCLC non-small cell lung cancer
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51.2 ± 12.7 min. Only one assessor was required to
perform the field walking tests, whereas the CPET
required two to three assessors. No adverse events
occurred.
Discussion
This is the first study to compare the validity of three
common field walking tests against the gold standard
measure of exercise capacity, CPET, in NSCLC. Our re-
sults demonstrate that in a cohort with operable stage I-
IIIb NSCLC the ISWT demonstrated greater criterion
validity than the 6MWT and ESWT with CPET. This is
likely due to the fact that the ISWT is incremental in a
similar manner to CPET, with the potential to test pa-
tients closer to their maximal exercise capacity. In con-
trast the 6MWD is performed at the participants own
pace and the ESWT is performed at a constant sub-
maximal speed. Our results are consistent with the only
other study examining the criterion validity of the ISWT
in lung cancer which also found the ISWT to be related
to CPET (r = 0.67) [42]. Studies have demonstrated that
pre-operative ISWT is a predictor of post-operative sur-
vival in NSCLC [42]; our study adds further to the litera-
ture in supporting the use of the ISWT in lung cancer.
Our study has shown that the ISWT and 6MWT have
excellent convergent validity suggesting they measure a
Fig. 2 Relationship between ISWT (a), 6MWD (b) and ESWT (c) with
CPET VO2peak. Abbreviations: 6MWT six minute walk test; CPET
cardio-pulmonary exercise test; ESWT endurance shuttle walk test;
ISWT incremental shuttle walk test; kg kilograms; minminutes; ml
millilitres; VO2peak peak oxygen consumption
Table 2 Test results
Variable Mean ± SD
Field walking tests
6MWD, m 499.0 ± 78
ISWT distance, m 410.0 ± 124.9
ISWT predicted VO2peak, ml/kg/min 14.4 ± 3.1
ESWT time, seconds 581.4 ± 383.5
ESWT level, completed 11 ± 3
CPET
Resting data
Heart rate, beats/min 90.7 ± 15.4
Systolic blood pressure, mmHg 127.6 ± 15.2
Diastolic blood pressure, mmHg 78.7 ± 12.4
Oxygen saturation, % 97.2 ± 1.3
Peak data
Heart rate, beats/min 131.2 ± 19.1
Systolic blood pressure, mmHg 167.9 ± 22.9
Diastolic blood pressure, mmHg 92.5 ± 19.9
Oxygen saturation, % 94.2 ± 6.3
VO2peak, ml/kg/min 17.8 ± 2.8
VO2peak, ml/kg/min, % predicted 76.0 ± 14.3
VO2peak, L/min 1.4 ± 0.4
VO2peak, L/min, % predicted 74.9 ± 18.4
VE, L/min 59.6 ± 15.5
Work 86.2 ± 33.9
Abbreviations: % percent; 6MWD six minute walk distance; CPET cardio-pulmonary
exercise test; ESWT endurance shuttle walk test; ISWT incremental shuttle walk test;
kg kilograms; L litres;minminutes; ml millilitres; mmHg millimetre of mercury; SD
standard deviation; VO2peak peak oxygen consumption
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similar construct to each other; however only the ISWT
is moderately related to CPET (and 6MWT is poorly re-
lated). The CPET measures a different construct to the
field walking tests and this may explain the discrepancy
between CPET and the field walking tests. The fact that
the ISWT is incremental may explain its closer associ-
ation to CPET. The ISWT and 6MWT are functional
tests, which measure functional exercise capacity and
walking capacity [31]. Results demonstrate that the field
walking tests are able to discriminate between partici-
pants with self-reported walking limitations which CPET
cannot. Similarly in COPD performance in the 6MWT
is closely related to activities of daily living [43]. On the
other hand CPET is a measure of cardiorespiratory fit-
ness. The main outcome of interest from CPET is
VO2peak, which is calculated as the product of cardiac
output and arteriovenous oxygen difference [16]. It is
commonly performed in lung cancer to determine
physiological status and risk stratification of patients be-
ing considered for lung resection [44]. Our findings sug-
gest that CPET and the field walking tests are not
interchangeable. There are times when CPET may be
preferred over the ISWT or 6WMD as an outcome
measure; for example in the case of prehabilitation when
patients may undergo aerobic exercise training with the
primary intent to improve cardiorespiratory fitness to be
fit enough for lung resection. Alternatively, exercise re-
habilitation programs for patients with advanced lung
cancer may use a field walking test as the measure of
interest when the primary intent is to improve func-
tional exercise capacity.
There are many advantages to non-laboratory field
walking tests: in a clinical setting these tests can be per-
formed quickly, simply (with little expertise required)
and relatively cheaply (little equipment required). Our
results show that all three field walking tests are quick
(less than 16 min), safe (no adverse events) and require
only one assessor. This means that these tests can easily
be performed by clinicians in their own setting, such as
an oncology ward, inpatient rehabilitation class or com-
munity rehabilitation setting to assess, re-assess or
monitor their patients. In a research study the ability to
perform measurement with few costs, minimal training
of research assistants and little time burden for partici-
pants (and potential drop-outs) is extremely advantageous.
Although the reproducibility of these field walking tests
(6MWT, ISWT, ESWT) has not been established specific-
ally in the lung cancer population, these tests have been
demonstrated to have high reproducibility in individuals
with chronic respiratory disease [31, 45]. It has been
shown in non-lung cancer respiratory populations that
there is a learning effect for the 6MWT and ISWT,
and therefore two tests are recommended according
to the ATS guidelines [15, 31, 45]. This methodology
was followed within this study.
The 6MWT is currently the most commonly used field
walking test in NSCLC [20]. It is likely that its
favourable use stems from the COPD literature. The
6MWT is an extremely robust measure of functional ex-
ercise capacity in COPD and has strong, well established
clinimetric properties, including excellent reliability
(ICC = 0.82-0.99), moderate validity (CPET VO2peak r =
0.4-0.6) and sensitivity to change [15, 31]. In COPD the
6MWT is the standard measure to evaluate pulmonary
rehabilitation efficacy [15]. Despite the fact that many
patients with lung cancer have COPD as a comorbidity
(35 % in our cohort), cancer cachexia and symptom clus-
ters such as fatigue, dyspnoea and pain [46, 47] are
unique in lung cancer; consequently patients with lung
cancer may perform differently to those with COPD. In
NSCLC there is little published evidence regarding the
clinimetric properties of the 6MWT. Previous research
has demonstrated the good predictive validity of the
6MWT for post-operative outcomes in NSCLC [48, 49]
and survival in patients with advanced NSCLC [50, 51].
The BODE index (which includes the 6MWT) is a
strong independent predictor of survival in inoperable
NSCLC [52]. Given the frequent use of the 6MWD in
lung cancer, further research is required to confirm our
findings and help to establish if use of the ISWT could
be substituted for the 6MWT in certain subgroups of
NSCLC. In this study we found the ISWT under-
predicted VO2peak in comparison to the CPET, albeit it
is within a small study sample. We hypothesise that this
may be due to the formula for prediction of VO2peak
not specifically being derived from a lung cancer popula-
tion for the ISWT and potentially that the ISWT may
not be a maximal test of functional capacity in all
patients.






(95 % CI), p value
Dyspnoea
6MWT 0.9 ± 1.1 3.4 ± 1.7 2.5 (1.9-3.2), p < 0.0005
ISWT 0.6 ± 0.7 4.2 ± 2.1 3.7 (2.7-4.6), p < 0.0005
ESWT 0.4 ± 0.6 4.3 ± 2.7 3.8 (2.5-5.2), p < 0.0005
CPET 0.7 ± 1.0 4.9 ± 1.9 4.2 (3.0-5.3), p < 0.0005
Leg fatigue
6MWT 1.1 ± 1.7 2.7 ± 2.6 1.7 (0.6-2.7), p = 0.003
ISWT 1.0 ± 1.4 3.5 ± 2.8 2.6 (1.5-3.6), p < 0.0005
ESWT 1.0 ± 1.3 3.7 ± 2.6 2.8 (1.5-4.1), p < 0.0005
CPET 0.7 ± 0.9 5.6 ± 3.1 4.9 (3.6-6.3), p < 0.0005
Abbreviations: 6MWT six minute walk test; CPET cardio-pulmonary exercise test;
CI confidence intervals; ESWT endurance shuttle walk test; ISWT incremental
shuttle walk test; SD standard deviation
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Our study did not find the 6MWT or ISWT to be closely
related to the ESWT. The ESWT was originally developed
to examine endurance capacity rather than functional exer-
cise capacity [23]. We are unaware of other studies which
have examined the clinimetric properties of the ESWT in
lung cancer; based on our results we do not recommend
this test at present to examine exercise capacity.
Muscle strength is a strong predictor of exercise per-
formance in COPD [53, 54] and peripheral muscle
power is related to performance in the ISWT in thoracic
cancer (r = 0.39) [18]. Previous research has established
that hand-grip strength is related to physical function (r
= 0.44) and performance status (r = 0.50) in patients with
heterogeneous cancers [55]. We hypothesized that hand-
grip strength, as a surrogate measure for whole body
strength, may be related to exercise capacity in NSCLC.
Our finding that hand-grip strength was poorly related
to performance in the field walking tests may be ex-
plained by the fact we measured hand-grip strength in-
stead of quadriceps muscle strength: future research is
required to explore this further.
Our study is limited by a small sample size and single
centre design. Participants had operable disease and
were a relatively fit cohort (ECOG-PS ≤ 2 rated by the
physician, only two individuals had VO2peak < 15 ml/kg/
min), therefore findings cannot be extrapolated to pa-
tients with inoperable disease or those with poorer func-
tional status or exercise capacity. Despite randomisation
of testing order and rest periods between tests, there
was a small statistically significant difference in baseline
leg fatigue between the first 6MWT and ESWT; this
may have led to poorer performance in the ESWT.
Conclusions
The ISWT is a valid and clinically applicable measure of
functional exercise capacity in operable NSCLC. The
ISWT has moderate criterion validity with CPET
VO2peak; is quick and safe to perform; and does not ap-
pear to have a floor or ceiling effect in this population.
Both the 6MWT and ESWT have poor validity with
CPET VO2peak. The ESWT has a ceiling effect and is
not currently recommend for use in NSCLC. The ISWT
appears to be the most promising field measure of exer-
cise capacity however findings need to be confirmed in
larger sample prior to translation into practice.
Abbreviations
6MWD: six minute walk distance; 6MWT: six minute walk test; %: percent;
ATS: American Thoracic Society; CPET: cardio-pulmonary exercise test;
CI: confidence intervals; COPD: chronic obstructive pulmonary disease;
COSMIN: Consensus-based standards for the selection of health status
measurement instruments; ECOG-PS: Eastern cooperate oncology group-
performance status; ERS: European Respiratory Society; ESWT: endurance
shuttle walk test; HRQoL: health-related quality of life; IQR: inter-quartile
range; ISWT: incremental shuttle walk test; kg: kilograms; L: litres; m: meters;
mHg: millimetre of mercury; min: minutes; ml: millilitre; NSCLC: non-small cell
lung cancer; PhD: doctor of philosophy; SD: standard deviation;
STROBE: Strengthening the reporting of observational studies in
epidemiology; VO2peak: peak oxygen consumption.
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